These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10977137)

  • 1. "Fast tracking" drug approvals: is consumer safety being compromised?
    Jacobsen K
    QRC Advis; 2000 Jun; 16(8):5-9. PubMed ID: 10977137
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 4. The issue of extralabel drug use.
    Kennedy JA
    J Am Vet Med Assoc; 1997 Dec; 211(11):1354. PubMed ID: 9394877
    [No Abstract]   [Full Text] [Related]  

  • 5. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 6. Premarket notifications of new dietary ingredients--a ten-year review.
    McGuffin M; Young AL
    Food Drug Law J; 2004; 59(2):229-44. PubMed ID: 15318394
    [No Abstract]   [Full Text] [Related]  

  • 7. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 8. The preemptive scope of the Medical Device Amendments of 1976.
    Sunshine PH
    Food Drug Law J; 1995; 50(1):191-212. PubMed ID: 10342991
    [No Abstract]   [Full Text] [Related]  

  • 9. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 10. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

  • 11. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 12. CBER's strategic plan: response from the physician/medical community.
    Parkman PD
    Food Drug Law J; 1996; 51(3):381-2. PubMed ID: 11797715
    [No Abstract]   [Full Text] [Related]  

  • 13. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 15. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 17. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 18. The ability of current biologics law to accommodate emerging technologies.
    Carter MJ
    Food Drug Law J; 1996; 51(3):375-80. PubMed ID: 11797714
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 20. Legal overprotection.
    Friedman JH
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.